Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: November 20, 2009
Last updated: August 11, 2016
Last verified: August 2016
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection. Participants will be randomized to receive 3 subcutaneous injections of either placebo or RO5217790 on Days 1, 8, and 15. Study assessments will be made at Baseline, at Month 3 and 6, and every 6 months thereafter for an overall of 2.5 years.

Condition Intervention Phase
Cervical Intraepithelial Neoplasia
Drug: Placebo
Drug: RO5217790
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of 5 X 10^7 PFU RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated With High Risk HPV Infection

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of participants with CIN2/CIN3 associated with HPV16 single infection who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision [ Time Frame: Month 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of participants who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision [ Time Frame: Months 6 ] [ Designated as safety issue: No ]
  • Percentage of participants who achieved Histologic response (Defined as CIN Grade less than [<] 2), determined by evaluation of tissue derived from surgical excision [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
  • Percentage of participants with viral clearance based on Roche Linear assay results [ Time Frame: Months 3 and 6 ] [ Designated as safety issue: No ]
  • Percentage of participants with immunologic response to HPV antigens [ Time Frame: Day 1 (predose), Days 8, 15, and 29, Months 3 and 6 ] [ Designated as safety issue: No ]
  • Percentage of Participants with at least one Adverse Events (AEs) [ Time Frame: Up to Month 30 ] [ Designated as safety issue: No ]

Enrollment: 206
Study Start Date: August 2009
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
Drug: Placebo
Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
Experimental: RO5217790
RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
Drug: RO5217790
RO5217790 will be administered at a dose of 5*10^7 pfu subcutaneously on Days 1, 8, and 15.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a diagnosis within 2 months prior to the first dose of RO5217790 of CIN 2/3 confirmed by colposcopy-directed punch biopsy; patients must have at least 1 quadrant of residual CIN2/3 disease remaining after biopsy. Entry to the trial will be allowed based on the local assessment of this criterion; however, CIN 2/3 diagnosis will have to be confirmed by the central pathologist for the purposes of analyzing the study
  • Have satisfactory colposcopy, i.e. the entire acetowhite or disease area as well as the entire squamocolumnar junction visualized by colposcopy
  • Have detection at screening of a single or multiple HR-HPV infection by analysis of liquid based cytology (LBC) material on the Roche Linear Array assay consistent with any of the trial strata as specified in study protocol

Exclusion Criteria:

  • Have colposcopically visible CIN2/3 disease extending over more than 2 quadrants
  • Have any anatomical condition of the cervix, including that resulting from previous cervical surgery, congenital malformation or other condition, that would interfere with a complete evaluation of the transformation zone and surveillance of CIN. If an endocervical curettage (ECC) is performed, and the endocervical curettings reveal CIN, patients are eligible as long as the endocervical lesion is directly extending from the primary lesion and is colposcopically visible in its entirety
  • Have vulvar (VIN) or vaginal (VAIN) intraepithelial neoplasia
  • Have atypical endometrial or glandular cells or evidence of carcinoma on biopsy
  • Have a serious, concomitant disorder, including active systemic infection requiring treatment
  • Have a prior history of or current malignancy other than adequately treated skin cancer (squamous cell cancer or basal cell carcinoma), unless the history of skin cancer is at the site of study treatment administration
  • Have a proven or suspected immunosuppressive disorder or autoimmune disease
  • Have any significant cardiac, hepatic or renal disease
  • Have active viral infections including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), cytomegalovirus (CMV), and Epstein barr virus (EBV) within 30 days of receiving study treatment. Mild viral infections such as Herpes Simplex Virus 1 (HSV-1) or common cold are not excluded
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01022346

  Hide Study Locations
United States, Alabama
Mobile, Alabama, United States, 36608
United States, Arizona
Phoenix, Arizona, United States, 85015
Phoenix, Arizona, United States, 85032
Tucson, Arizona, United States, 85712
Tucson, Arizona, United States, 85724-5078
United States, California
Colton, California, United States, 92324
Los Angeles, California, United States, 90027
United States, Colorado
Colorado Springs, Colorado, United States, 80910
United States, Connecticut
Stamford, Connecticut, United States, 06904
United States, District of Columbia
Washington, District of Columbia, United States, 20010
United States, Florida
Lake Worth, Florida, United States, 33461
Miami, Florida, United States, 33136
Plantation, Florida, United States, 33324
Sarasota, Florida, United States, 34239
South Miami, Florida, United States, 33143
West Palm Beach, Florida, United States, 33409
United States, Georgia
Atlanta, Georgia, United States, 30322
Augusta, Georgia, United States, 30912
Decatur, Georgia, United States, 30034
United States, Louisiana
Marrero, Louisiana, United States, 70072
United States, Massachusetts
Framingham, Massachusetts, United States, 01702
United States, Missouri
Kansas City, Missouri, United States, 64139
United States, Nebraska
Lincoln, Nebraska, United States, 68510
United States, Nevada
Las Vegas, Nevada, United States, 89030
Las Vegas, Nevada, United States, 89128
United States, New Jersey
Lawrenceville, New Jersey, United States, 08648
United States, New York
Brightwaters, New York, United States, 11718
Bronx, New York, United States, 10461
United States, North Carolina
New Bern, North Carolina, United States, 28562
Winston-salem, North Carolina, United States, 27103
United States, Ohio
Englewood, Ohio, United States, 45322
Gallipolis, Ohio, United States, 45631
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
West Reading, Pennsylvania, United States, 19611
United States, South Carolina
Columbia, South Carolina, United States, 29201
Greenville, South Carolina, United States, 29615
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Nashville, Tennessee, United States, 37232
United States, Texas
Austin, Texas, United States, 78705
Houston, Texas, United States, 77004
McAllen, Texas, United States, 78503
United States, Utah
Sandy, Utah, United States, 84070
United States, Virginia
Norfolk, Virginia, United States, 23502
Antwerpen, Belgium, 2020
Brussel, Belgium, 1090
Bruxelles, Belgium, 1070
Edegem, Belgium, 2650
Gent, Belgium, 9000
Leuven, Belgium, 3000
Tienen, Belgium, 3300
Hus, Finland, 00029
Kuopio, Finland, 70211
Oulu, Finland, 90220
Tampere, Finland, 33520
Bordeaux, France, 33076
Dijon, France, 21079
Nantes, France, 44093
Paris, France, 75231
Reims, France, 51092
Strasbourg, France, 67098
Puerto Rico
San Juan, Puerto Rico, 00909-1711
San Juan, Puerto Rico, 00935
Bilbao, Vizcaya, Spain, 48013
Barcelona, Spain, 08036
Madrid, Spain, 28040
Madrid, Spain, 28942
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01022346     History of Changes
Other Study ID Numbers: NV25025  2008-006946-24 
Study First Received: November 20, 2009
Last Updated: August 11, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Hoffmann-La Roche:
Cervical intraepithelial neoplasia

Additional relevant MeSH terms:
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type processed this record on October 27, 2016